AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, LinkedIn or Instagram.
Agepha Pharmaceuticals
AGEPHA PHARMA is a well-established European manufacturer of pharmaceutical products for several medical fields including ophthalmology. With over 70 years of continuous research and development of innovative products, AGEPHA Pharma is today a medium-sized multinational company with a broad range of products distributed worldwide. We care about developing products that truly benefit healthcare and can improve overall quality of life. All our products are of outstanding quality due to our rigid compliance with the highest European pharmaceutical manufacturing standards.
Alchimia
Alchimia is one of the leading European manufacturers of medical devices for ophthalmic surgery and human tissue banking with the aim of improving the daily routine of the medical personnel and the quality of life of patients.
Alcon Management Sa
Alcon is the global leader in eye care, dedicated to helping people see brilliantly. With an over 75-year heritage, we are the largest eye care device company in the world, with complementary businesses in Surgical and Vision Care. Being a truly global company, we work in 60 countries and serve patients in more than 140 countries. We have a long history of industry firsts, and each year we commit a substantial amount in Research and Development to meet customer needs and patient demands
Alimera Sciences Europe Ltd.
Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit our website.
Apellis Switzerland GmbH
Apellis is a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing medicines. At Apellis, we are committed to developing transformative therapies for people living with Geographic Atrophy (GA) by regulating complement, a part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases such as GA, where there are currently no treatment options available. For more information about Apellis please visit our website and if you would like to learn more about geographic atrophy, visit geographicatrophy.eu.
Aprofol AG
Aprofol AG is focused on reduced Folate for the treatment of chronic diseases. An altered microcirculation is considered a risk factor for degenerative eye diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR) and glaucoma. An inadequate microcirculation is the reason for systemic and/or local deficiencies of micronutrients e.g. bioactive Folate. Aprofol AG supported a recently published study with glaucoma patients and Ocufolin®. After 12 weeks the Homocysteine-level and the retinal venous pressure (RVP) was significantly reduced.